Methotrexate revisited.
D000293:Adolescent; D000328:Adult; D000468:Alkalies / Q000627:therapeutic use; D000630:Aminopterin / Q000627:therapeutic use; D000818:Animals; D001853:Bone Marrow / Q000187:drug effects; D001859:Bone Neoplasms / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D007668:Kidney / Q000187:drug effects; D007676:Kidney Failure, Chronic / Q000139:chemically induced / Q000517:prevention & control; D002955:Leucovorin / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000188:drug therapy; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000188:drug therapy*; D013936:Thymidine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000468:Alkalies; D005493:Folic Acid Antagonists; D014750:Vincristine; D000630:Aminopterin; D002955:Leucovorin; D013936:Thymidine; D008727:Methotrexate